Why Peptide Drugmakers Are Betting Big on Factories

Soaring demand is forcing peptide drugmakers to rethink strategy, shifting focus from discovery toward manufacturing scale, reliability, and cost control

5 Feb 2026

The market for peptide therapeutics is entering a more industrial phase, as rising demand forces drugmakers to focus less on discovery alone and more on how medicines are made at scale.

Peptide drugs, once a specialised niche, are increasingly used in high-volume treatments for diabetes, obesity and cardiovascular disease. As patient numbers grow, manufacturing efficiency and reliable supply are becoming central to competition in the sector.

Recent dealmaking and capital spending point to a strategic shift. Many companies are expanding production capacity while continuing to build their clinical pipelines, seeking to balance innovation with cost control and execution certainty. Investments in plants, equipment and selective acquisitions are now seen as essential to support long-term growth.

One of the most significant transactions was Novo Holdings’ $16.5bn acquisition of contract manufacturer Catalent. Following the deal, Novo Nordisk took ownership of three Catalent fill-finish sites to strengthen its in-house manufacturing capacity for high-demand medicines, including peptide-based therapies. The move underlined how access to large-scale, high-quality production has become a competitive advantage as supply tightens.

Eli Lilly has taken a similar approach, announcing multibillion-dollar investments in new US manufacturing facilities to produce peptide medicines and other active pharmaceutical ingredients. The company has said the spending reflects expectations that demand for chronic peptide treatments will remain strong and that internal capacity can reduce the risk of shortages.

Industry analysts note that as peptide therapies move into broader use, manufacturing performance is becoming as important to market access as clinical results. The ability to produce consistently, at lower cost and at higher volumes, is increasingly shaping commercial success.

The shift is also accelerating consolidation. Smaller biotechnology groups with promising peptide candidates face pressure to show credible routes to economical production. Larger pharmaceutical companies are responding by acquiring manufacturing assets, technologies or specialist expertise to reduce development and supply risks.

Although building and running peptide manufacturing facilities requires high upfront investment and strict regulatory compliance, the direction of travel is clear. Peptide therapeutics are moving into the pharmaceutical mainstream, and companies that secure production scale now are positioning themselves for longer-term leadership.